Healthcare Industry News: Cambridge Heart
News Release - October 29, 2007
Cambridge Heart Welcomes John F. McGuire and Keith M. Serzen to the Board of DirectorsBEDFORD, Mass.--(HSMN NewsFeed)--Cambridge Heart, Inc. (OTCBB: CAMH ), today announced the election of John F. McGuire (Jack) and Keith M. Serzen to serve on its Board of Directors. Mr. McGuire was the President and Chief Executive Officer managing the American Red Cross Blood Business and the disaster relief efforts and humanitarian projects through more than 800 chapters nationwide. Mr. Serzen, the Chief Operating Officer, for ResMed, Inc. Americas, is responsible for overseeing ResMed’s daily activities which ensure the proper development, improvement and operation of the Company and the products it delivers.
“We are extremely honored to have Jack and Keith join our Board,” said Robert P. Khederian, Chairman and Interim CEO of Cambridge Heart, Inc. “Their outstanding experience in sales, operations and strategic planning will help drive Cambridge Heart to a higher level of performance and realize our goal of incorporating the Company's Microvolt T-Wave Alternans technology into the standard clinical workup of patients at risk of sudden cardiac death.”
Prior to joining the American Red Cross, Mr. McGuire was President of Whatman, PLC Filtration Products, an international leader in separations technology and provider of materials and devices to laboratory and healthcare markets. During his tenure at Whatman, Mr. McGuire successfully restructured the Company to maximize its growth and profitability. In addition, Mr. McGuire has held prominent positions for over 22 years in the field of biomedical technology and the blood banking industry.
Mr. Serzen has over 27 years experience in sales and marketing of hospital supplies, including cardiovascular devices. Prior to ResMed, Mr. Serzen served as Chief Executive Officer of Theracardia, Inc., a startup medical device company, and as President/CEO of Acculight, Inc., a laser-oriented research and development company. From 1995 to 1998, he was Vice President of Marketing and Sales for Heartstream, Inc., a manufacturer of automatic external defibrillators, where he was responsible for developing, implementing and directing the worldwide marketing and sales strategy. From 1983 to 1995 Mr. Serzen held senior sales, marketing and general management positions with Nellcor, the world-wide supplier of pulse oximetry and patient safety monitoring equipment.
About Cambridge Heart, Inc.
Cambridge Heart (www.cambridgeheart.com) is engaged in the development and commercialization of products for the non-invasive diagnosis of cardiac disease, particularly the identification of those at risk of sudden cardiac arrest. The Company's products incorporate its proprietary Microvolt T-Wave Alternans measurement technologies, coupled with its patented Spectral Analytic Method and ultra-sensitive disposable electrode sensors. Only Spectral Analytic Method MTWA tests are reimbursed by Medicare under its National Coverage Policy that covers patients with a wide variety of cardiac symptoms. Other major insurers in the U.S. also have coverage policies for the test. The T-Wave Alternans test is included in the Guideline for Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death jointly developed by the American College of Cardiology (ACC), the American Heart Association (AHA), and the European Society of Cardiology (ESC). The Company, founded in 1990, is based in Bedford, Massachusetts, and is traded on the OTCBB under the symbol CAMH.
This press release contains forward-looking statements that involve risks and uncertainties. Any statements made as part of this press release that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the foregoing, when used in this press release, the words “anticipate”, “believe”, “estimate”, “intend” and “expect”, and similar expressions are intended to identify such forward-looking statements. The Company’s actual results may differ materially from the results suggested by these statements. Factors that may cause or contribute to such differences include, but are not limited to, those discussed in the Company’s Form 10-K filed with the Securities and Exchange Commission. In addition, any forward-looking statements represent our estimates only as of today and should not be relied upon as representing our estimates as of any subsequent date. While we may elect to update forward-looking statements at some point in the future, we specifically disclaim any obligation to do so except as may be legally necessary, even if our estimates should change.
Source: Cambridge Heart
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.